Every time we receive an AI alert,Tianfeng SecuritiesOn April 24, a report titled “Excellent Operation and Steady Growth, Product Leading and Seeking the Future” was released.Research reportsay, giveSteady Medical(300888.SZ, latest price: 58.6 yuan) Buy rating.The reasons for the rating mainly include: 1) 22Q1 revenue of 2.32 billion yuan, an increase of 2.4%, excluding incentive expenses, a 66.6% increase from the parent chain; 2) 2) health consumer goods business: 2021 revenue of 4.054 billion yuan (accounting for 50.44% of the total), an increase of 15.27% %; 3) 2022Q1 health consumer goods business revenue is 890 million yuan (accounting for 38.33% of the total), an increase of 8.76%; 4) 2021 grossinterest rateThe same decrease of 9.67pct to 49.88%, a decrease of 1.77pct compared with 2019;interest rateThe same decrease of 14.98pct to 15.42%, an increase of 3.48pct compared with 2019. Risk reminder: raw material costs rise; store efficiency growth slows down; terminal consumption is weak, and the new crown epidemic.
AI comments:Steady Medical12 in the past monthbrokerageThe research report paid attention, bought 10 companies and increased their holdings in 2 companies.
(Article source: Daily Economic News)
Article source: Daily Economic News
Responsible editor: 33
Original title: Tianfeng Securities gave Steady Medical a Buy rating: Excellent operation and steady growth, leading products for the future
Solemnly declare: Oriental Fortune.com releases this information for the purpose of disseminating more information and has nothing to do with the position of this site.